BetterInvesting Magazine Update on Stride Inc.  and Amgen Inc.

BetterInvesting Magazine Update on Stride Inc. and Amgen Inc.

Stride Inc.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Stride Inc. (NYSE:LRN) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for investors' informational and educational use.

The fundamental data is eye-opening; investors can view Stride's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., here .

A full report on Stride will appear in the August 2025 issue of BetterInvesting Magazine.

The same issue of BetterInvesting Magazine will also include a fundamental review of Amgen Inc. (NASDAQ:AMGN), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective.

Committee members are Daniel J. Boyle , CFA; Marisa Bradbury , CFA; Philip Keating , CFA; Walter J. Kirchberger , CFA; Anne Nichols , CFA; and Dan Rutter , CFA.

Doron P. Levin , an editor of the magazine, serves as the committee's chairperson.

Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

About BetterInvesting:

BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

Follow us on LinkedIn , Instagram and Facebook .

Contact: 877-275-6242

Cision View original content: https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-stride-inc-nyse-lrn-and-amgen-inc-nasdaq-amgn-302466516.html

SOURCE NAIC-BetterInvesting

News Provided by PR Newswire via QuoteMedia

AMGN:US
The Conversation (0)
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidence that CardiolRx™ reduces inflammation-driven... Keep Reading...
Pink liquid being pipetted into rows of clear test tubes.

Transforming Disease Detection with AI-Driven Biological Insights

Artificial intelligence (AI) is fundamentally reshaping biotechnology and healthcare, unlocking the secrets hidden within complex biological data. Machine learning in genomics and proteomics is transforming how diseases are detected, monitored and treated. Central to this revolution are... Keep Reading...
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market.This allowance fortifies Cardiol's... Keep Reading...
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume... Keep Reading...
Appendix 4C and Quarterly Activities Report - September 2025

Appendix 4C and Quarterly Activities Report - September 2025

Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - September 2025Download the PDF here. Keep Reading...
Nextech3D.ai Reports Strong 20% Q2 Sequential Revenue Growth With Gross Margins of 88% For the Three Months Ended September 30, 2025 ("Q2 2026")

Nextech3D.ai Reports Strong 20% Q2 Sequential Revenue Growth With Gross Margins of 88% For the Three Months Ended September 30, 2025 ("Q2 2026")

Key Year-over-Year Highlights:Gross Margin Expansion: Increased to 88%, up from 71%, representing a 17-point improvement.Operating Loss Reduced by 65%: Narrowed to $439,000, from $1.25 million in 2024.Net Loss Reduced by 63%: Improved to $482,000, compared to $1.31 million last year.Deferred... Keep Reading...

Latest Press Releases

Related News